1. Home
  2. PETS vs GRDX Comparison

PETS vs GRDX Comparison

Compare PETS & GRDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo PetMed Express Inc.

PETS

PetMed Express Inc.

SELL

Current Price

$1.26

Market Cap

28.4M

ML Signal

SELL

Logo GridAI Technologies Corp.

GRDX

GridAI Technologies Corp.

SELL

Current Price

$4.66

Market Cap

28.6M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
PETS
GRDX
Founded
1996
N/A
Country
United States
United Kingdom
Employees
N/A
N/A
Industry
Retail-Drug Stores and Proprietary Stores
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
28.4M
28.6M
IPO Year
2003
2016

Fundamental Metrics

Financial Performance
Metric
PETS
GRDX
Price
$1.26
$4.66
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
★ 130.4K
94.5K
Earning Date
08-13-2026
11-18-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 21.95
EPS
★ N/A
N/A
Revenue
★ $273,800,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$2.24
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.27
$1.87
52 Week High
$4.10
$6.93

Technical Indicators

Market Signals
Indicator
PETS
GRDX
Relative Strength Index (RSI) 14.90 63.73
Support Level N/A $4.51
Resistance Level $1.91 $5.30
Average True Range (ATR) 0.04 0.46
MACD -0.01 0.15
Stochastic Oscillator 3.28 80.59

Price Performance

Historical Comparison
PETS
GRDX

About PETS PetMed Express Inc.

PetMed Express Inc is a nationwide direct-to-consumer pet pharmacy and online provider of prescription and non-prescription medications, foods, supplements, supplies, and vet services for dogs, cats, and horses. It markets and sells directly to consumers through its websites, toll-free numbers, and mobile application, offering convenience, price, speed of delivery, and customer service. It provides access to branded pharmaceuticals, generic medications, compounded prescription medications, over-the-counter health and wellness products, prescription and non-prescription food, pharmacy fulfillment, and AutoShip capabilities. Its digital platform offers pet healthcare solutions for chronic conditions, including allergies, arthritis, anxiety, kidney-related conditions, and hyperthyroidism.

About GRDX GridAI Technologies Corp.

GridAI Technologies Corp, formerly known as Entero Therapeutics Inc, is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The company's programs address unmet needs in GI health and include: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for indications including gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.

Share on Social Networks: